# Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

> **NCT03727750** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 51 (actual)

## Conditions studied

- ECG
- Pharmacokinetics
- Safety

## Interventions

- **DRUG:** Gemtuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT03727750
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-03
- **Primary completion:** 2021-04-27
- **Final completion:** 2021-04-27
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03727750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03727750, "Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03727750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*